In vivo antitumor efficacy with significant tumor growth inhibition in multiple models with varying levels of FOLR1 expression Highly promising safety results in non-human primates, enabling a broad ...
Mablink Bioscience (“Mablink”), a biotechnology company dedicated to advancing cancer therapy with next-generation antibody-drug conjugates (ADCs), today announced that preclinical efficacy and safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results